<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02458079</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-AH-02</org_study_id>
    <nct_id>NCT02458079</nct_id>
  </id_info>
  <brief_title>Pentoxyphilline Versus Fecal Microbiota Therapy in Severe Alcoholic Hepatitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment for severe alcoholic hepatitis patients not eligible for steroid therapy is a&#xD;
      dilemma. Pentoxyfilline has been shown to have no improvement in outcomes as per current&#xD;
      studies and liver transplantation is with great risk of recidivism in this difficult to treat&#xD;
      cohort of patients. Dysbiosis forms the central role in severe alcoholic hepatitis patients&#xD;
      and modulation of gut microbiota by way of healthy donor fecal transplantation could prove to&#xD;
      be a novel way to treating these patients who are ineligible for standard therapy. This study&#xD;
      utilizes correction of dysbiosis in severe alcoholic hepatitis and surveys outcomes with the&#xD;
      same with respect to survival and liver disease severity scores.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Actual">July 27, 2016</completion_date>
  <primary_completion_date type="Actual">July 27, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at 3 months</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in SOFA (Sequential Organ Failure Assessment) score at 3 months</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in CTP (Child Turcotte Pugh Score) score at 3 months</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in MELD (Model for End Stage Liver Disease) score at 3 months</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short term mortality in both groups</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Pentoxiphylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stool Microbiota Transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxiphylline</intervention_name>
    <arm_group_label>Pentoxiphylline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stool microbiota transplantation</intervention_name>
    <arm_group_label>Stool Microbiota Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with a diagnosis of severe alcoholic hepatitis who are steroid&#xD;
             ineligible, are non responders or are intolerant&#xD;
&#xD;
          -  Severe alcoholic hepatitis defined as Maddrey's Discriminant Function Score (4.6 x (PT&#xD;
             test - control))+ S.Bilirubin in mg/dl of more than 32 OR a patient of alcoholic&#xD;
             hepatitis (defined as AST:ALT ratio &gt; 2:1) who presents with any grade of hepatic&#xD;
             encephalopathy&#xD;
&#xD;
          -  Conventional therapy defined as oral steroid therapy (Wysolone Â® 40mg once a day for 7&#xD;
             days)&#xD;
&#xD;
          -  Failure of therapy defined as a Lille Model Score (http://www.lillemodel.com) of &gt;0.45&#xD;
             at day 8 of steroid therapy OR emergence of complications of steroid therapy or&#xD;
             intolerance to steroid protocol or ineligible for steroid therapy.&#xD;
&#xD;
          -  Ineligibility for steroid therapy includes - Renal dysfunction, evidence of active&#xD;
             sepsis or foci of sepsis, gastro intestinal bleeding and disseminated intravascular&#xD;
             coagulation, steroid intolerance, steroid related uncontrolled hyperglycemia which&#xD;
             precludes therapy, uncontrolled diabetes mellitus&#xD;
&#xD;
          -  A Psychologist will be arranged for recipients who are on Fecal Transplant protocol&#xD;
             for psychological support throughout the period of one week, during which the&#xD;
             transplant procedure will be performed&#xD;
&#xD;
               1. Healthy persons who are willing for faeces donation have to be a close family&#xD;
                  member&#xD;
&#xD;
               2. The donor will be required to give a written consent for faeces donation&#xD;
&#xD;
               3. Once consent is taken, the donor will have to undergo the following screening&#xD;
                  measures:&#xD;
&#xD;
                    1. Clostridium difficile toxins A and B by EIA&#xD;
&#xD;
                    2. Routine bacterial culture for enteric pathogens in stool&#xD;
&#xD;
                    3. Ova and parasites&#xD;
&#xD;
                    4. Blood serology for viruses - human immunodeficiency virus [HIV, type 1 and&#xD;
                       2] HAV IgM, HBsAg, anti HCV Ab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active gastrointestinal bleeding&#xD;
&#xD;
          -  Intracranial bleeding&#xD;
&#xD;
          -  Multi-organ failure on mechanical ventilation&#xD;
&#xD;
          -  On high inotropic support&#xD;
&#xD;
          -  Paralytic ileus&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Failure to provide consent&#xD;
&#xD;
          -  Have abnormal bowel motions&#xD;
&#xD;
          -  Have abdominal complaints&#xD;
&#xD;
          -  Have symptoms indicative of irritable bowel syndrome&#xD;
&#xD;
          -  Have extensive travel history or predisposing factors for potentially transmittable&#xD;
             diseases&#xD;
&#xD;
          -  Have chronic alcohol intake&#xD;
&#xD;
          -  Have history of substance abuse&#xD;
&#xD;
          -  Are less than 18 years or more than 60 years of age&#xD;
&#xD;
          -  Have HIV and Hepatitis Risk factors&#xD;
&#xD;
          -  Have enteric infections&#xD;
&#xD;
          -  Have inflammatory bowel disease history&#xD;
&#xD;
          -  Have chronic constipation or diarrhea&#xD;
&#xD;
          -  Have prior abdominal surgery or GI neoplasms&#xD;
&#xD;
          -  Have Metabolic Syndrome&#xD;
&#xD;
          -  Have Systemic Autoimmunity&#xD;
&#xD;
          -  Have atopic diseases&#xD;
&#xD;
          -  Have food and respiratory allergies&#xD;
&#xD;
          -  Have any chronic pain syndromes&#xD;
&#xD;
          -  Have chronic Neurologic disorders&#xD;
&#xD;
          -  Have Neurodevelopmental disorders&#xD;
&#xD;
          -  Have had antibiotics for any indication taken within the last 2 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 23, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

